Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases ...

Fintel reports that on March 14, 2025, Cantor Fitzgerald initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a ...

Choline Chloride, the Company’s investigational IV phospholipid substrate replacement therapy, as a source of choli TARA-002 demonstrated compelling efficacy and was generally well-tolerated ...

A new review highlights how gut microbiome imbalances contribute to cardiovascular disease by altering short-chain fatty ...

Its candidate UNR844 (lipoic acid/choline ester chloride) – acquired with Encore Vision in 2017 – works by restoring the elasticity of the lens.

Its candidate UNR844 (lipoic acid/choline ester chloride) – acquired with Encore Vision in 2017 – works by restoring the elasticity of the lens. AbbVie hopes for another lift to its fast ...

Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs ...